Dart is a combination analgesic used in situations involving certain distressing symptoms. It is commonly applied when symptoms interfere with daily functioning, and is relevant when supportive symptom management is appropriate. In clinical practice, these combinations are indicated for the relief of mild to moderate pain and discomfort associated with feverishness.

The medication is commonly used across conditions presenting with acute episodes, helping to address symptom clusters that may become intense or disruptive. This includes symptoms related to physical discomfort such as tension headaches, musculoskeletal aches, neuralgia, and primary dysmenorrhoea (menstrual pain), alongside the reduction of fever associated with illnesses like the common cold or influenza.

“The primary goal is to provide supportive relief during episodes of heightened systemic burden.”

Dart is applied in clinical settings that involve acute or unstable symptom patterns, such as the temporary strain of recurrent symptoms or localized discomfort following minor procedures, including post-dental pain. It provides supportive relief when symptoms interfere with routine activities, and may assist with maintaining functional stability when acute discomfort becomes noticeable.

---

Quick Fact: Relief for Acute Episodic Discomfort Dart is commonly used for managing conditions characterized by periods of heightened, non-severe symptoms that disrupt daily comfort, such as recurrent headaches or flu-like malaise.

Regulatory References

1. EFDA Summary of Product Characteristics

Official Population Eligibility for Dart

Regulatory agencies define eligibility for the Dart combination (Paracetamol, Propyphenazone, Caffeine) based on age, underlying health conditions, and allergy status.

Classification	Rule (Official Regulatory Status)
Populations Allowed	Adults and adolescents aged 12 years and older. Older adults are permitted, but caution is advised.
Absolutely Contraindicated	Children under 12 years of age. Patients with hypersensitivity to any ingredient, known allergy to other pyrazolone or NSAID-like painkillers, bone marrow deficiencies, acute hepatic porphyria, or those taking another Paracetamol product concurrently.
Not Recommended	Women who are pregnant or breastfeeding due to official risk factors associated with the components.

Eligibility is also restricted by comorbidity. Use requires caution and medical advice in patients with renal or hepatic impairment, chronic alcoholism, gastric ulcers, bleeding disorders, or conditions sensitive to stimulants, such as arrhythmia or hyperthyroidism. Severe liver disease or end-stage renal failure are explicit contraindications.

Interactions with Other Medicines and Products

The medicinal product Dart is a combination of active ingredients, typically including Paracetamol (an analgesic/antipyretic), Propyphenazone (an NSAID), and Caffeine (a central nervous system stimulant). Due to this composite nature, its interaction profile is the sum of its components, necessitating caution when combined with various substances.

Significant Interaction Categories:

Category	Examples of Interacting Medicines
Enzyme Inducers	Phenytoin, Carbamazepine, Rifampicin, Butabarbital
Enzyme Inhibitors	Cimetidine, Oral Contraceptives, Metoclopramide
Other Analgesics	Other Paracetamol-containing products, NSAIDs, Salicylates
CNS Stimulants	Ephedrine, Theophylline

Combinations with enzyme-inducing agents like certain anti-seizure medicines (e.g., Carbamazepine, Phenytoin) or Rifampicin can increase the rate of metabolism of the components in Dart, potentially reducing efficacy or increasing the risk of toxic metabolites. Conversely, drugs that inhibit liver enzymes, such as Cimetidine, may decrease the metabolism of some components, raising their plasma concentration and the risk of adverse effects. Drugs like Metoclopramide may alter the absorption rate of Paracetamol. Concomitant use with other medications containing Paracetamol is a major restriction due to the heightened risk of liver toxicity.

Non-Medicinal Interactions:

• Alcohol: Consumption of alcohol is strongly advised against due to a significant increase in the risk of serious liver damage from the Paracetamol component.
• Tobacco/Smoking: Nicotine and other substances in tobacco can increase the clearance of Caffeine, potentially reducing its stimulating effect.

Dual-Target Binding and Cellular Bridge Formation

The DART mechanism involves the drug acting as an engineered molecular bridge, simultaneously attaching to two specific biological structures (antigens) found on the surfaces of two different cells. This highly selective dual-target binding forces the two cell types into close physical proximity, creating the foundation for a directed physiological effect.

Targeted Pathway Modulation and Signal Rerouting

The forced interaction created by the drug's binding directly modulates signaling pathways by either triggering or blocking communication between the two linked cells. This targeted pathway interference alters the natural cascade of cellular responses, modulating pathways driven by increased activity and contributing to specific changes in physiological function. This action represents a rerouting of native cellular communication, establishing a programmed interaction that governs the downstream system-level physiological modulation.

How to Use Dart

Dart is an oral Fixed-Dose Combination (FDC) tablet containing Paracetamol, Propyphenazone, and Caffeine, intended for the management of acute, temporary symptoms. The administration of this medicine is based on established dosing limits and usage constraints, defining its role as an as-needed, short-term measure.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral administration only.
Standard Single Dose	1 to 2 tablets for adults (≥ 16 years).
Dosing Frequency	Doses may be repeated after a minimum interval of 4 hours, up to a maximum of four times daily.
Maximum Daily Dose	The total dose must not exceed 8 tablets in any 24-hour period.
Duration of Use	Intended for short-term use; prolonged use requires medical supervision and is not recommended for more than a few days without consulting a physician.

---

Procedural and Population-Specific Instructions

The tablet must be swallowed whole with water and should not be crushed or chewed. Administration is flexible regarding meals, as the tablets can be taken with or without food. If stomach upset occurs, taking the tablet with food is advised.

For adolescents aged 12–15 years, the maximum single dose is 1 tablet, with a total limit of 4 tablets in 24 hours. The medicine is not recommended for children under 12 years. Patients with hepatic or renal impairment must seek medical advice before use, as dose adjustments may be necessary due to the composition of the product. Due to the combination of active ingredients, patients must ensure they do not use this product with any other paracetamol-containing medications and must avoid excessive intake of caffeine from dietary or medicinal sources.

Research Evidence / Overview of Studies for Dart

Evidence for Acute Mild to Moderate Pain

Research exploring the effects of the Dart formulation focuses primarily on research exploring outcomes related to physical discomfort, which includes the evaluation of acute, non-severe pain symptoms. Studies exploring how symptoms change over time commonly utilize short-term Randomized Controlled Trials (RCTs) and pooled statistical analyses. In these trials, the fixed-dose combination (FDC) was evaluated against a placebo (dummy pill) and its individual active components.

The main outcomes measured were related to changes in patient-reported outcomes describing perceived discomfort and the time taken until a symptom change was observed. The studies explored immediate pain endpoints in adult populations using standardized models, such as post-operative dental pain, which is often used as a defined model for acute, moderate pain states in research protocols. Findings describe patterns observed in these studies, specifically related to the onset of a measured change and the measured pain intensity reduction within a few hours of administration.

Evidence for Headache and Primary Dysmenorrhoea

Dart was studied for its use in conditions characterized by fluctuating or episodic manifestations, specifically tension-type headaches and primary dysmenorrhoea (menstrual pain). Research examined patients experiencing acute or disruptive episodes, focusing on outcomes related to functional imbalance and physical discomfort.

For headache, studies monitored individuals during an acute episode, exploring short-term symptom changes such as the time needed until a pain-free state was reported and measurements of pain recurrence rates. Findings indicate patterns related to acute symptomatic changes in these specific conditions. Similarly, research explored primary dysmenorrhoea, where studies focused on episodes where symptoms become more noticeable, measuring changes in pain intensity during the acute menstrual cycle phase.

Study Landscape: Consistency and Research Gaps

Research describing these short-term measurements contributes to the available evidence base for fixed-dose analgesic combinations. However, the results apply only to the specific populations studied in these acute pain models. Long-term effects are not fully established; there is limited information for how the observed patterns may continue or change if the medicine is used frequently over weeks or months. Data for certain groups remain insufficient, especially for older adults, and subgroup findings are uncertain for these specific demographics. The evidence quality varies across studies, often utilizing pooled statistical analyses to evaluate data related to the combination's components. More research is needed to characterize the potential effects of the formulation across a broader spectrum of conditions and demographic groups beyond the short-term, acute setting.

Key Studies & References

1. Summary of Product Characteristics for Paracetamol/Propyphenazone/Caffeine Combination (Example Regulatory Document)
2. WHO Collaborating Centre for Drug Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification System - N02BB54

Common questions about Dart (FAQ)

---

Q: Is Dart the same type of medicine as other drugs I see advertised?

Dart is officially described as a Fixed-Dose Combination (FDC) product. This means it contains three different active substances: an analgesic (pain reliever), an NSAID-like pain reliever, and a central nervous system stimulant. This combination structure is what differentiates it from many single-ingredient pain medicines available.

---

Q: How is Dart different from older medicines used for the same condition?

The fixed-dose combination structure is described as offering a synergistic effect. Regulatory-supported evidence describes the combination as providing a synergistic effect, which may include a faster onset of effect from one component and a period of efficacy consistent with the recommended dosing interval, distinguishing it from single-agent formulations.

---

Q: Why does the FDA/EMA package insert mention liver monitoring?

Official labeling references the risk of liver damage and hepatic dysfunction associated with the paracetamol component of Dart. The official product information notes that this risk is greater when factors such as overdose, chronic alcohol use, or concomitant use with certain other medicines that affect liver enzymes are present.

---

Q: Are there different strengths or formulations of Dart available?

Yes, official regulatory filings confirm that the combination of Paracetamol, Propyphenazone, and Caffeine is available in different strengths and ratios in the various territories where the product is approved for use. The exact strength is determined by the specific product formulation and its regulatory approval.

---

Q: How long does the effect of one dose of Dart last?

Regulatory data on the Paracetamol component indicates a period of efficacy of approximately 3 to 4 hours. This timeframe is consistent with the minimum interval established in official guidance for repeating the dose.

---

Q: Does taking Dart affect my immune system?

The medicine’s official safety profile describes documented adverse reactions within the Blood and Lymphatic System disorders. These include very rare occurrences of conditions such as Agranulocytosis (involving a reduction in white blood cells) and Thrombocytopenia (a low platelet count).

---

Q: What happens if I stop taking Dart suddenly?

Official documentation notes that prolonged or frequent use of this type of pain reliever is associated with the risk of developing a Medication-Overuse Headache (MOH). This is a consideration noted in official documentation when the medicine is used frequently.

---

Q: Does Dart have an official warning about drowsiness or driving?

The official labeling contains statements noting that if effects such as dizziness or drowsiness are experienced, driving or operating machinery is not recommended. These are listed as possible documented effects of the medicine.

---

Q: Is there an official patient leaflet or guide for Dart?

Yes, regulatory bodies require that a Package Leaflet (PL) or similar patient information guide is published and provided to the user with the medicine packaging. This document contains information specifically tailored for the user.

---

Q: What is the half-life of Dart?

The pharmacokinetic data in regulatory documents state that the half-life for the Paracetamol component is typically 1 to 4 hours. The Propyphenazone component's half-life is cited as being approximately 77 minutes when used in this specific combination.

---

Q: Is it normal to have a slight headache when first using Dart?

Official documentation notes that headache is listed as a possible undesirable effect of the medicine. Regulatory information indicates that while the medicine is used to treat headaches, headache is also a documented adverse reaction.

---

Q: Is Dart used to treat any conditions other than the primary one it was approved for?

The official indications listed in product information are broad. They include symptomatic relief for headache, toothache, menstrual discomfort, pain and fever associated with colds and flu, and postoperative and rheumatic pain.

---

Q: What is the regulatory status of Dart (e.g., approved, pending)?

The presence of official labeling and public health advisories from major global regulatory bodies confirms that the medicine has achieved regulatory approval for marketing in the territories where those official documents apply.

How to Store and Dispose of Dart?

The storage and disposal of Dart (Paracetamol, Propyphenazone, and Caffeine tablets) must adhere strictly to official regulatory labeling to ensure product integrity and safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 25 C.
Protection	Keep protected from light and moisture.
Packaging	Store in the original container/blister pack.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Do not use the medicine after the expiration date (EXP) shown on the packaging. Unused or expired Dart tablets must be disposed of according to local requirements and regulations. The medicine must not be thrown away via wastewater or general household waste. Consult a pharmacist for guidance on proper disposal methods.